Press Releases
-
Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline
Sep 28, 2026
-
The University of Turin Adopts Openwater’s Open-Motion Device to Study Muscle Blood Flow and Vascular Responses
Researchers in the University’s Integrative Physiology Lab will evaluate Openwater’s wearable platform for studying muscle blood-flow dynamics and vascular responses to nervous system activity, with potential future applications in noninvasive neural communication
Sep 28, 2026
-
Systech Launches New All-in-One Pharma Packaging and Serialization Stations
Sep 29, 2026
-
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
Sep 30, 2026
-
Sygnature Discovery establishes DEL screening collaboration with X-Chem
Sep 20, 2026
-
Johnson County ClinTrials (JCCT) Rebrands as Sequoia Clinical Research
New identity unites three site organizations under one banner as company expands beyond its vaccine-trial roots into multi-therapeutic clinical research site network
Sep 23, 2026
-
Astoriom Acquires Additional UK Storage Business to Expand Capacity and Service Offerings
• Acquisition of Sampled’s UK facility strengthens Astoriom’s position as a trusted provider of secure, compliant and quality-led sample stability and biorepository storage solutions • Offers broader coverage, additional technical expertise and increased operational resilience to help safeguard critical samples
Sep 23, 2026
-
New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
Veeva Systems today announced Veeva Study Builder Agent, a new AI solution that configures Veeva EDC and Veeva DQS (Data Quality System) directly from a study protocol.
Sep 23, 2026
-
New Publication Associates SherpaPak® Cardiac Transport System with Lower Costs Across Heart Transplant Care
Published in the special Focus Issue on Innovations in Heart Transplantation in the Journal of Cardiac Failure, the GUARDIAN-Heart analysis across 18 U.S. transplant centers identifies $14,982 in net per-patient cost savings across multiple measured categories spanning post-transplant support, hospital care, organ preservation, and readmissions.
Sep 21, 2026
-
BOC Sciences Announces October 2026 Webinars on Vaccine Development and DNA-Encoded Chemistry
Sep 22, 2026
-
Complex-molecule specialist Shilpa CDMO launches at CPHI Milan
Sep 15, 2026
-
Upperton granted MHRA licence for Annex 1 aligned sterile manufacturing facility
Upperton, a UK-based contract development and manufacturing organisation (CDMO), today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved a variation to its existing Manufacturing and Importation Authorisation for Investigational Medicinal Products (MIA(IMP)) licence, extending its scope to include the company’s new Annex 1-aligned sterile manufacturing facility at Trent Gateway, Nottingham.
Sep 16, 2026
-
TSRL, Inc. Rebrands as TSRLabs Ahead of Its Next Chapter of Growth
New name, visual identity and website position Ann Arbor preclinical CRO for its next phase of scientific growth
Sep 14, 2026
-
Psychedelic Medicines Approach a Historic FDA Approval Milestone with Safety Under Scrutiny
The FDA's historic psychedelic hearing highlighted a critical question: how can psychedelic medicines become accessible without compromising patient safety? As developers move closer to potential approvals, regulators must balance clinical evidence, professional oversight, workforce training, geographic access and long-term safety.
Sep 14, 2026
-
FDA Approves AstraZeneca’s Etcamah, Bringing ctDNA-Guided Treatment to Breast Cancer
AstraZeneca’s Etcamah has received FDA accelerated approval for ctDNA-guided treatment in HR-positive, HER2-negative breast cancer with ESR1 mutations. The decision could establish an earlier treatment-switch strategy based on molecular changes before cancer becomes visible on scans.
Sep 9, 2026
-
FibroFind appoints leading transplant physician Professor Andrew Fisher as Chief Medical Officer
Sep 9, 2026
-
Research uncovers new driver of immunotherapy resistance in pancreatic cancer
Targeting a signal released by dormant cancer cells could help overcome resistance to immunotherapy and improve cellular therapies for pancreatic cancer.
Sep 9, 2026
-
Qinecsa selected as technology partner for Africa’s new continent-wide medicines safety platform
Qinecsa has been selected as technology partner for AfriVigilance, the African Medicines Agency’s new continent-wide medicines safety surveillance platform, with implementation already underway.
Sep 9, 2026
-
Panther Life Sciences Appoints Mounir Hanana as Chief Executive Officer
Hanana brings 25 years of experience scaling global technology, consumer, and manufacturing businesses at Amazon and Procter & Gamble. Founder Carlos Bhola continues as Executive Chairman, leading strategy, product vision and corporate development. Hanana joins as Panther begins commercializing its SmartPatch™ platform, starting with cosmetics and medical aesthetics and expanding to therapeutic applications.
Sep 9, 2026
-
Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models
The study evaluated NetraAI across clinical datasets in schizophrenia, major depressive disorder and pancreatic cancer, benchmarking the technology against eight industry-standard predictive models. Results show NetraAI's biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested.
Sep 9, 2026


